KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Convertible Debt: 2009-2024

Historic Convertible Debt for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $628.5 million.

  • Ionis Pharmaceuticals' Convertible Debt fell 9.66% to $567.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.1 million, marking a year-over-year decrease of 9.66%. This contributed to the annual value of $628.5 million for FY2024, which is 0.50% up from last year.
  • Ionis Pharmaceuticals' Convertible Debt amounted to $628.5 million in FY2024, which was up 0.50% from $625.4 million recorded in FY2023.
  • Ionis Pharmaceuticals' Convertible Debt's 5-year high stood at $628.5 million during FY2024, with a 5-year trough of $540.1 million in FY2020.
  • Moreover, its 3-year median value for Convertible Debt was $625.4 million (2023), whereas its average is $625.4 million.
  • Data for Ionis Pharmaceuticals' Convertible Debt shows a peak YoY increased of 24.25% (in 2020) over the last 5 years.
  • Over the past 5 years, Ionis Pharmaceuticals' Convertible Debt (Yearly) stood at $540.1 million in 2020, then rose by 14.62% to $619.1 million in 2021, then increased by 0.50% to $622.2 million in 2022, then climbed by 0.50% to $625.4 million in 2023, then climbed by 0.50% to $628.5 million in 2024.